Literature DB >> 6199518

Renal cell carcinoma--angioinfarction.

W K Mebust, J W Weigel, K R Lee, G G Cox, W R Jewell, E C Krishnan.   

Abstract

In our experience the mortality rate in 46 patients who underwent angioinfarction for renal cell carcinoma was 4 per cent. Fever, ileus and leukocytosis were noted in 86 to 90 per cent of our patients. The use of absolute ethanol as a medium for renal infarction was associated with a significant incidence of damage to other organs. A 30 per cent decrease in tumor volume following angioinfarction using absorbable gelatin sponge and Gianturco coils was noted in 75 per cent of the patients. There was no evidence of metastatic tumor reduction and we could not document any significant decrease in operative time or blood loss. It would appear that there is some increased survival rate in patients with metastasis who are given adjuvant immune ribonucleic acid therapy. However, the numbers in our series are not significant to draw any definite conclusion. It is apparent that patients treated with infarction, delayed nephrectomy and medroxyprogesterone acetate did not have any significant survival over those treated with palliative nephrectomy or chemotherapy. The macrophage maturation assay may be useful during clinical followup.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199518     DOI: 10.1016/s0022-5347(17)50320-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Role of embolization in the treatment of renal masses.

Authors:  David Li; Bradley B Pua; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 2.  Surgery for metastatic renal cell cancer.

Authors:  Shomik Sengupta; Bradley C Leibovich; Michael L Blute; Horst Zincke
Journal:  World J Urol       Date:  2005-06-30       Impact factor: 4.226

3.  Pilot study of transcatheter arterial ethanol embolization under closed renal circuit for large renal cell carcinomas.

Authors:  Satoru Murata; Hiroyuki Tajima; Shiro Onozawa; Shinichiro Kumita; Yukihiro Kondo; Kazuhiro Nomura
Journal:  Eur Radiol       Date:  2008-03-20       Impact factor: 7.034

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.